Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw that, picked up some more. Business plan looks good to me
CHND going again
news out
QuantGate Systems Inc. Appoints Independent DirectorsPress Release | 09/15/2020
Toronto, Ontario and New York, New York--(Newsfile Corp. - September 15, 2020) - QuantGate Systems Inc. (OTC Pink: QGSI) announces the appointment of Mr. Robert Seguin, and Mr. Wayne Welter as independent directors to the board of the Company (the "Board").
Mr. Ilan Yosef, Chief Operating Officer of QuantGate Systems Inc., commented: "We are delighted to welcome Mr. Robert Seguin and Mr. Wayne Welter, to Quantgate. We are confident that their extensive experience in various fields will help us further strengthen our internal controls and our corporate governance, and help prepare us for our next stage of growth."
Mr. Robert Seguin is a multinational and multilingual senior manager with over 30 years of institutional experience and management of Securities Dealers in various countries. Throughout Robert's career, he has demonstrated successes in start-up environments, focused on business development, and generated increasing revenue and profitability through organized and targeted communication, marketing and salesmanship. Robert brings excellent organizational skills, and is highly motivated and innovative in approaching new challenges.
Wayne Welter has been involved in the Financial Services industry for over 25 years, as a Portfolio Manager and Investment Advisor, providing comprehensive wealth planning and investment management services to a select group of high net worth clientele, business owners, and institutional clients.
During the past 15 years, Mr. Welter has provided advisory and consulting services to numerous North American and International companies on business development and strategic growth, with a focus on foreign market entry. Mr. Welter has developed an extensive global network of strategic banking, legal, investment and management relationships, and has successfully participated in, and financed projects in Europe, the Middle East, Asia and China.
New website is up https://xcelplusint.com/
News out
Strattner Technologies Partners with Pareteum to Launch Mobile Virtual Network Operator
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Pareteum Corporation (Nasdaq: TEUM), a global cloud communications platform company, announced today that it has partnered with Strattner Technologies LLC, a subsidiary of Strattner Financial Group (OTC: SCNG), to launch the Strattner Voice brand, a GSM cellular network complementing its satellite communications network Strattner.Space.
Strattner Technologies will utilize Pareteum's Experience Cloud platform to enter the mobile communications market with the mission to reconnect Americans with their friends, family and business associates both in the US and across the world, in these pandemic times. Strattner is bridging the gap between cellular and satellite networks on a single smartphone device. Strattner.Space, the Satellite communications division of the company, has strategically combined with Strattner Cellular division to bring this product solution to market. David Blunk, CTO of Strattner Group stated, "We are very excited about the opportunity to go to market with a unified cellular solution that integrates rural market coverage on satellite technology."
The Pareteum Experience Cloud delivers connected services in over 200 territories worldwide and its reach continues to expand. The Pareteum Experience Cloud enables a host of powerful mobility, customer engagement, analytics, and intelligence services over the world's largest unified global network. This includes global Wi-Fi and cellular connectivity, inflight Wi-Fi service, application-to-person (A2P) messaging, location intelligence, and more. The platform's SaaS model enables rapid time to market for service launches and expansions and allows brands to pay-as-they-scale.
"We are thrilled to partner with Strattner Technologies to help launch their Mobile Virtual Network through our robust Experience Cloud platform," said Bart Weijermars, Pareteum's CEO. "The Pareteum Experience Cloud provides the flexibility and scalability to power a diverse range of services that will enable Strattner to enter the mobile communications market."
"We see tremendous growth in the satellite communications market and after launching our satellite communications service, Strattner.Space, we are thrilled to announce our partnership with Pareteum to launch our mobile network called Strattner Voice which will be available to the growing satellite-smartphone device market," said Timo Strattner, CEO of Strattner Group. "Our mission is to reconnect America. "
About Pareteum Corporation
Pareteum is an experienced provider of Communications Platform as a Service solutions. Pareteum empowers enterprises, communications service providers, early stage innovators, developers, IoT, and telecommunications infrastructure providers with the freedom and control to create, deliver and scale innovative communications experiences. The Pareteum platform connects people and devices around the world using the secure, ubiquitous, and highly scalable solution to deliver data, voice, video, SMS/text messaging, media, and content enablement. For more information please visit: www.pareteum.com.
Hope so too. And have a great week as well.
Me too!
Yeah, lots of bagholders
I bought 100 at 12, just sold. Crazy
CHND today
It's been a long wait, but well worth it
It's moving .35 hit
Amarillo Biosciences to Initiate Low-Dose Interferon Clinical Trials to Treat COVID-19, Appoints Interferon Specialist Dr. Manfred Beilharz to Scientific Advisory Board
Amarillo, TX, Sept. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), the world leader in low-dose non-injectable interferon research, is pleased to announce the appointment of Dr. Manfred Beilharz, Associate Professor at The University of Western Australia and renown pioneer in interferon research, to the Company’s Scientific Advisory Board.
Based on the Company’s past successful clinical research using low-dose interferon, Dr. Beilharz will work closely with ABI and its research collaborators in initiating several clinical trials this year. These trials will primarily be focused on developing a therapeutic for COVID-19, as well as the continuation of the Company’s late-stage treatments for thrombocytopenia and Sjögren’s syndrome. ABI Chairman & CEO, Dr. Stephen T. Chen, remarked, “We are excited to be working again with Dr. Beilharz who has contributed tremendously to the interferon research field and there is a high degree of confidence that our non-injectable interferon development program, Veldona, will prove to be an effective therapeutic for these targeted indications based on supporting clinical research.”
In relation to COVID-19, clinical data has shown low-dose interferon alpha effective against other coronaviruses such as H1N1 and SARS. Previously, a published study for a collaborative phase 2b influenza trial conducted by Dr. Beilharz, “Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an in?uenza pandemic year” demonstrated 150 IU interferon alpha delivered orally with ABI’s proprietary formulated Veldona lozenge significantly reduced the severity of symptoms in males aged 50 years or more and showed potential to enhance vaccine-induced protection against influenza. Other published clinical and non-clinical studies confirm low-dose interferon’s unique mechanism of action provide the medical-scientific rationale for ABI’s clinical development strategy for Veldona. Applying clinical studies towards COVID-19 is a logical next step.
Dr. Beilharz has stated, “The current COVID-19 pandemic urgently requires prevention and treatment options, particularly for frontline medical staff and at-risk groups, and oral low-dose type 1 interferon is a readily available public health option with an extensive published literature. It’s exciting that in the Hubei Province in China, where this pandemic originated, they have released details of a study where they treated over 2,000 frontline medical workers with oral interferon nose drops to try and protect them. There have been no reports of any contracting COVID-19, while in the controls - another 2,000 nurses and doctors working in the same province - 50 to 60 per cent were infected with COVID-19. That is a pretty clear demonstration of the prophylactic value of this.” Dr. Beilharz will be managing the Company’s COVID-19 clinical trials in Australia.
ABI is also preparing to resume its clinical trials for thrombocytopenia, an immune condition causing low platelet count prevalent in patients that experience hepatitis-C relapse and other debilitating conditions such as chemotherapy treatment. In a 2014 published study, “A Double-Blind Randomized Controlled Study to Evaluate the Efficacy of Low Dose Oral Interferon-Alpha in Preventing Hepatitis C Relapse,” Dr. Chau-Ting Yeh, Director, Liver Research Center at Chang Gung Memorial Hospital (Taiwan), was the co-author and principal investigator for a phase 2 clinical trial in which it was discovered that 500 IU low-dose interferon alpha was surprisingly effective in exerting a significantly expedited recovery of platelet count in chronic hepatitis C patients having moderate to severe liver fibrosis. As a result of this study ABI applied for and received four thrombocytopenia related patents. Dr. Yeh will be managing the Company’s subsequent thrombocytopenia clinical trials in Taiwan.
“As we move forward with planned Veldona clinical trials, both Dr. Beilharz and Dr. Yeh’s decades of research experience will be critical in successful execution and the establishment of effective collaborations with other stakeholders. Our goal will be to diligently advance the Veldona clinical trial program with the vision of developing Veldona-based new treatments for COVID-19 patients, as well as patients with difficult-to-treat indications like thrombocytopenia and autoimmune disorders such as Sjögren’s syndrome who are in urgent need for therapeutic solutions,” said Dr. Stephen T. Chen.
About Dr. Manfred Beilharz
A leader in interferon research, Dr. Beilharz has extensive knowledge of type-1 interferons in relation to diseases of viral, autoimmune and neoplastic origin, as well as principal investigator experience in numerous interferon research studies including previous collaboration with ABI in an oral low-dose interferon alpha “Winter Colds and Flu” phase IIb clinical trial in Perth, Western Australia (2008-2010). Dr. Beilharz serves on the scientific advisory boards of US and Australian Biotech companies, consults widely, and is on the editorial board of the “Journal of Interferon and Cytokine Research.” He has worked full time in biomedical research since 1982 holding posts at Monash University, the University of Western Australia, Johns Hopkins University, Oxford University and the Australian Neuromuscular Research Institute.
About Dr. Chau-Ting Yeh
Dr. Yeh is currently a Director of the Liver Research Center at Chang Gung Memorial Hospital and is a leading researcher in hepatology with extensive experience in molecular biology and treatment of hepatitis B and hepatitis C, Hepatocarcinogenesis and marker-guided anticancer treatment. His ground-breaking research publication “Efficacy of Low Dose Oral Interferon-alpha in Preventing Hepatitis C Relapse” was instrumental in ABI obtaining its current patents related to thrombocytopenia. Dr. Yeh has an M.D. from National Taiwan University, Medical School and Ph.D. from USC, Department of Internal Molecular Microbiology and Immunology. He has received numerous awards including Distinguished Research Faculty Member, Chang Gung University (2012) and Taiwan Ministry of Science & Technology, FutureTech Demo and Breakthrough Award (2019).
And probably FNAM, spiked a week ago.
News out
Theralink(R) Technologies Achieves Milestone, CLIA Certification for its Golden, CO Laboratory
Expect to Begin Receiving, Testing and Billing for Patient's Breast Cancer Tumor Specimens in Q4 2020
DENVER, CO / ACCESSWIRE / September 9, 2020 / OncBioMune d/b/a Theralink Technologies (OTC PINK:OBMP), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical Laboratory Improvement Amendments (CLIA) certification for its Golden, Colorado laboratory, retroactively effective as of January 8, 2020.
The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS) to regulate laboratories that test human specimens. The results of the Colorado CLIA Certification Program survey showed that all CLIA Condition-level requirements were met, adhering to the highest standards in the industry.
"We are thrilled to receive CLIA certification for our Golden, CO laboratory, as this was truly a team effort that began two years ago. Receiving CLIA certification is a key step in our growth strategy as we plan to expand our testing capabilities and uncover key insights from human trials in cancer treatment," said Mick Ruxin, M.D., President and CEO of Theralink Technologies, Inc. "With CLIA certification, we expect to begin receiving, testing, and billing for patient's breast cancer tumor specimens in the fourth quarter of 2020."
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling company, located in Golden, Colorado, that uniquely specializes in patented, phosphoprotein, and protein biomarker assay services that target multiple areas of oncology. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. We intend to improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
EVGI 1.50
WOW Inc. to Expand Into Worlds Largest Cannabis Market
DENVER, Sept. 04, 2020 (GLOBE NEWSWIRE) -- World of Weed Inc. (OTC PINK: WOWU) is pleased to announce its growth strategy in the U.S. Cannabis market by executing a Letter of Intent to grant franchise rights to PDX Partners Inc. (OTC PINK: PDXP). Both parties strongly feel the Southern California market for cannabis is both lucrative and in its primal infancy. Also key is the national impact both socially and economically of California and especially Southern California. CEO of WOWI Inc., Anthony C. Russo states, “We have closely watched the California legalization of recreational cannabis and its impact. With this recent dip in sales we feel the long term prognosis and economic viability is even more attractive thus prompting our current entry.” “The current California opportunity with PDXP and my long term relationship with their CEO, I believe, opens infinite positive possibilities,” said Russo. Pat Johnson PDXP CEO states, “We are excited to franchise World of Weed branded storefronts and WOW set up grows to raise the bar in efficiencies and quality products to the California consumers. We believe that World of Weed’s processes and proven track record set them apart from the others and that their proof of concept during good and bad pricing markets makes them the leader in Colorado.” The arrangement looks to Brand the nationally trade marked World of Weed name and products in what most consider the biggest potential cannabis market in the USA. Final agreements are currently in document review and will be executed as both CEO’s and their counsel’s sees fit.
Data from Leafly’s 2020 Cannabis Jobs Count indicates that legal cannabis sales in California contracted 18% year-over-year to $2.03 billion in 2019. That took a toll on cannabis employment in the Golden State. From Jan. 2019 to Jan. 2020, about 8,600 previously legal cannabis jobs in California became illegal cannabis jobs or disappeared entirely.
That was due in large part to the sunsetting of medical marijuana-era collectives. Industry veterans and Canadian newcomers alike lost their shirts last year. California remains the nation’s largest cannabis employer, with an estimated 39,804 full-time jobs, but the industry remains tightly constrained by a tough licensing and regulatory environment.
But here’s the flip side: Legal excise tax revenues surged 60.5% year-over-year to an estimated $305.30 million in 2019 (up from $190 million in 2018). There are now more than 600 open stores and delivery services, with an estimated 300 new stores expected to open in 2020. There are 5,400 licensed farms, ensuring adequate legal supplies.
"This endeavor will expand the World of Weed brand into the lucrative and immense Southern California cannabis market which is the largest legal market in the world,” said CEO Anthony Russo.
J. Craig Holding Corp. Makes Equity Investment in the Motion Picture Production Entitled “MVP” Written and Directed by Nate Boyer
HUNTINGTON BEACH, CA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- J. Craig Holding Corp., fka Ultra Pure Water Technologies, Inc. (OTC: UPWT), an accelerator and incubator for innovative businesses, intellectual properties and assets, announced it has taken part in the financing of the motion picture production written and directed by Nate Boyer, currently entitled “MVP”.
This will be the first of many assets announced within the J. Craig Holding Corp. portfolio and its first movie financing. Ultra Pure Water Technologies CEO, Jerry C. Craig, who recently submitted the required paperwork for an official name change to FINRA, is no stranger to Hollywood production. Mr. Craig has worked in or on multiple films in his career.
“I am excited to work with Nate on this project. He is a true patriot and after reading the script, I was moved by its overall message. I love football, have tremendous respect for our military troops and knew I had to be a part of this production,” stated Jerry C. Craig.
Under the financing agreement, the company shall be entitled to recoup their original Investment Contribution, with a 20% premium from gross receipts. The company is also entitled to a cut as high as 33% of the overall profits above certain benchmarks.
Currently entitled “MVP”, which stands for Merging Vets & Players, features cameos from NFL greats and a star-studded celebrity cast. The movie takes a deeper look into the sensitive subject of suicide, a tragedy that happens way too often amongst our military veterans as they transition into society as a civilian. Nate Boyer plays a retired Marine living in a shelter known famously as “The Barracks” in Hollywood, California, who struggles to get off the street, find a job and a home. An ex-NFL star now dealing with being a civilian himself, no longer in the limelight, he too must deal with the day to day struggles of accepting and transitioning to his new life outside of sports. The two men find camaraderie on the sweat stained mat of a gym. After Boyer’s character loses his best friend due to suicide, the ex-NFL star accepts the responsibility of protecting Boyer’s character from doing the same. They are two fighters, from different fields, with a similar battle at home. Two people, searching for a purpose and a reason to live.
“This film is about the genesis of the nonprofit MVP (vetsandplayers.org) which I co-founded alongside Jay Glazer. Combat vets and former professional athletes often struggle greatly with transition once the uniform comes off. We would never compare war to playing a pro sport, but I did both and I can tell you that the locker room, camaraderie, brotherhood, structure and issues with identity loss are remarkably similar. It’s a blessing to work with Mr. Craig and am truly humbled to have him assist in our film and believe in my vision,” added Boyer.
The movie, which is set to shoot this fall, hopes to be ready for market by the summer of 2021. Similar movies such as The Wrestler, Garden State, Into the Wild, Good Will Hunting, The Fighter, Jarhead and 8 have seen tremendous success in the independent film industry.
YouTube Video on Nate Boyer and Merging Vets & Players:
Yeah, weird moves. I have some more shells in my account, so ...
Glad you made some money on it. Could have made more too, but happy so far, still have 2k left. Almost 100k volume.
Looked like a squeeze, crazy move
CIIT wow, 8.00
CIIT wow, .90
J. Craig Holding Corp. Receives New Corporate CUSIP Number
HUNTINGTON BEACH, CA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- J. Craig Holding Corp., fka Ultra Pure Water Technologies, Inc. (OTC: UPWT), an accelerator and incubator for innovative businesses, intellectual properties and assets, received email confirmation of their new CUSIP number for One World Universe.
Caren Currier, CFO, stated, “This is another milestone in our transition from Ultra Pure Water Technologies. Our new ticker will be the last piece of the puzzle to go along with the name and CUSIP change which will help us better reflect our new business.”
The holding company, which will have initial assets in the sports technology, equipment and entertainment industry, will have an additional corporate update within the next 24 hours. The announcement will lay out our current corporate achievements, and share what our company goals will be for the next 30 days. Reminder, all company announcements will be made available via press release, corporate website and social media platforms. Shareholders are asked to follow our social media account on Twitter at www.twitter.com/JCHC_UPWT for additional updates.
About J. Craig Holding Corp. (OTC: UPWT)
J. Craig Holding Corp. is a California based holding company that focuses on acquisition and support of both distressed and emerging companies within a multitude of industry sectors. The company actively seeks targets in which it can partner with or acquire to accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. For more information visit: www.JCHoldingCorp.com
I own VIVC for a long time, made some profit on the FS, still holding quite a few. Could be a nice play with some patience
Nice news
Nice news!
Yeah, very nice move
News out
Omnicanna CEO, Greta Gaines with Kelly Carroll from The Fly, Examine the Hempery Brands' Successful Focus on Health and Wellness, the Corona Virus Outbreak and Potential Cannabinoid Solutions, High-Tech Infusions, and Being a Part of the CSi-EDP Economic Development Plan Management Team
RALEIGH, NC / ACCESSWIRE / August 31, 2020 / Omnicanna Health Solutions, Inc. (OTC PINK:ENDO), a U.S. Company specializing in Industrial Hemp Commercialization and Formulation-based health and wellness solutions, is pleased to release Omnicanna CEO Greta Gaines does an interview with Kelly Carroll from The Fly.
Greta provides insight to industrial hemp commercialization and her passion to produce 100% natural health and wellness solutions, Omnicanna's competitive edge, the challenges of the industry, and the Coronavirus and possible cannabinoid-based solutions. Greta shares some of Omnicanna's strategy and thoughts on the hemp industry explaining how the hemp and CBD industry is getting more and more saturated with people that are just focused on making a quick buck in the ‘green rush'. Omnicanna differentiates itself clearly as being a medical and industrial research focused company.
Omnicanna's infused high-tech strategy lines up great with the economic necessity for consumer to go online to purchase all types of products non-stop online as the Corona Virus has left us crippled. Greta points out how customer anxiety and concern with general health due to the Covid- 19 virus has put Omnicanna at the right place at the right time with some upcoming exciting new and familiar solutions and products to release. The two advanced technology deals include two real-time negotiating marketplace technologies; www.livenegotiator.com and the soon to be released Industrial Hemp Real-time Trading Marketplace.
The advanced live-negotiating technology is designed to harness the power of the internet and empower every consumer looking for products online and every product seller with an instant ability to negotiate privately online with multiple parties and close deals instantly, all at the same time online in real-time.
A full copy of the article can be found here. https://bit.ly/328Swku
"It was great speaking with Kelly Carroll from The Fly. I was happy that the publication and article gave me a way to share some of Omnicanna's thoughts on the industry and our products. I look forward to doing more interviews in the future to support communication about who we are, what we are doing, and our thoughts on the industrial hemp market in general and how we are infusing science and technology with 100% natural goodness." concludes Greta Gaines, Chief Executive Officer, Omnicanna Health Solutions.
About The Hempery
The Hempery products truly are nature's perfect skin care because they contain an abundance of pure hemp seed oil and coconut oil. Hemp seed oil has been called "nature's perfect food for humanity." Hemp seed contains rich proteins and fatty acids including Omega-3 and Omega-6's. Hemp seed contains all the essential amino acids necessary for human life. Our proprietary formulas are rich in hemp seed oil and coconut oil. These products are flavored with organic essential oils that makes them ultra-appealing and effective. The base of all the products in The Hempery collection is the unique plan of an ultra-nutritious treat for the skin. Your skin can now experience the miracle of these benefits every day.
About Hemp Tasty
Hemp Tasty is the food portion of Omnicanna's The Hempery product line. Recipes are created by international award-winning Chef Wayne Howey of Jupiter, Florida. Chef Wayne is creating a line of hemp-based foods starting with a spice line, a sauce line, and baking products that will be rolled out over time.
About CANNABIS SCIENCE CSI-EDP
http://edp.cannabisscience.com/
Join in the Education and Economic Development of your Community, your Company, or Yourself now!
On July 28, Omnicanna announced it had joined the Cannabis Science Economic Development Plan, a self-driven community program focused on job creation and education. Omnicanna joined an exclusive licensing group headed by Live Negotiator Corporation. The licensing group shares the revenues derived from each technology released based on their financial support and operational involvement. Gaines said she sees the benefits of joining in adding
Omnicanna's talents to the cooperative and expanding everyone's resources, especially research. "The EDP team is focused on FDA initiatives, educational components, state by state distribution and dosing," she said. "It also allows us to tap into and benefit from others expertise to get products launched with cooperation for observational statements with Cannabis Science and all the other Partners we want."
About Omnicanna Health Solutions, Inc.
Omnicanna Health Solutions, Inc. is currently developing new natural hemp-based products based on innovative formulations to utilize the unique and potent benefits of the hemp plant. Medicinal properties of hemp have been known and applied for thousands of years. With the aid of scientific research, Omnicanna Health Solutions is translating such knowledge into development of effective hemp formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.
CIIT cheap at .18. CFO sold all shares and CEO big part recently. https://www.otcmarkets.com/stock/CIIT/disclosure Might see change of control
GLED on bid now
Gone now
Yeah, me too
ELVG added some
ASPD addition today, already trades on grey market. CEO https://www.linkedin.com/in/stephane-de-baets-7a99007a/
https://www.aspencoin.io/index.html
https://www.businesswire.com/news/home/20200824005320/en/%C2%A0tZERO-ATS-Begins-Trading-St.-Regis-Aspen
New CEO http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=XRXINTERNATIONALENTERTAINMENTH%20P980000543511&aggregateId=domp-p98000054351-86003deb-08af-4f04-8442-35dec397644c&searchTerm=XRX%20International%20Entertainment%20Holding%20Group&listNameOrder=XRXINTERNATIONALENTERTAINMENTH%20P980000543511
This is him https://larrymoskowitzpa.com/